)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Adocia
Adocia (ADOC) investor relations material
Adocia Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary29 Oct, 2026
Executive summary
Cash was €8.4m at September 30, 2026; an October €7m financing and cost reductions extend the cash runway to Q1 2028.
BioChaperone technology is the development priority, with partnership discussions and paid R&D collaborations intended to expand commercial opportunities.
Financial highlights
Revenue was €0 in Q3 2026 and €43k for 9M 2026, versus €1.437m for 9M 2025; 2026 revenue came from a BioChaperone peptide-combination feasibility study.
Cash position was €8.4m at September 30, 2026, including €2.4m in 2025 Research Tax Credit received in August.
Activity-related cash burn was €12.4m for 9M 2026 versus €13.2m for the comparable 2025 period, including PGE repayments.
Net financial debt was €1m, consisting of the unpaid shareholder loan; the remaining €0.7m in state-guaranteed loans was fully repaid during Q3.
Outlook and guidance
October financing and cost reductions extend the cash runway to Q1 2028; September 30 cash alone was expected to fund activities until early Q2 2027.
A US$20m milestone is expected upon BC Lispro marketing authorization in China; receipt would extend the cash runway to 2029, with subsequent double-digit sales royalties.
Tonghua Dongbao finalized the BC Lispro China application dossier and is preparing submission.
Distribution preparations are underway for BC Lispro territories outside China and certain Asian countries where rights are retained.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Adocia
- Net loss narrowed to €8.6M on €1.3M revenue, with cash runway into Q2 2027 but funding risk persists.ADOC
H1 2026 - Revenue up, net loss down, and cash runway extended to Q2 2026 with major clinical milestones ahead.ADOCH2 2024
- Strong cash position and positive R&D progress support strategic focus on BioChaperone®.ADOCQ2 2026 TU
- Innovative peptide platforms drive growth in diabetes and obesity therapeutics.ADOCInvestor presentation
- BC Lispro/BCLIS achieved superior postprandial and daily glucose control with non-inferior HbA1c.ADOCStudy result
- Cash runway secured to Q2 2027; BioChaperone® prioritized after positive study results.ADOCQ1 2026 TU
- Pipeline advances and new financing extend cash runway to Q2 2027 despite wider net loss.ADOCH2 2025
- H1 2025 saw higher revenue and cash inflow, but net loss increased to €9.3 million.ADOCH1 2025
- Net loss €8.9M, €10.3M cash, funding to Q3 2025, key programs advancing.ADOCH1 2024
Next Adocia earnings date
CMD 202624 Nov, 2026
Adocia
Next Adocia earnings date
CMD 202624 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Adocia SA is a biotechnology company focused on the development of innovative therapies for the treatment of diabetes and other metabolic diseases. The company specializes in creating advanced formulations of already approved therapeutic proteins, aiming to improve their efficacy and patient experience. Adocia's technology platforms are designed to optimize the delivery and performance of these treatments, particularly in the field of insulin therapy. The company is headquartered in Lyon, France, and its shares are listed on the Euronext Paris exchange.